Invivyd selects RSV antibody candidate VBY329; 2H 2026 IND readiness targeted

Invivyd, Inc.

VBY329 showed 1.5x greater potency vs nirsevimab, 1.2x vs clesrovimab against authentic RSV strains.
Up to ~500-fold enhanced neutralization vs nirsevimab-resistant variants in pseudovirus assays.
Half-life extension technology expected to expand protective window vs standard of care.
Pediatric RSV prophylaxis market estimated $3-4B annually globally by 2030.
Additional discovery efforts for ultra-long half-life RSV antibodies for elderly/immunocompromised.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.